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   Total acid phosphatase （TAP）， prostatic acid phosphatase （PAP）， alkaline phosphatase
（AlkP） were determined on the serum of the prostatic cancer patients． TAP， PAP and LDH
were exarnined also on the bone marrow fluid．
    1． The serum TAP was high in 91．3％ of the patients with bohe metastasis and in 43．2％
of those without the metastasis． 56．8％ of those showing high TAP had bone metastasis．
    2． Elevation of the serum PAP was seen in 86．9％ of the rnetastasis group and in 37．8％
of the non－metastasis group． 58．5％ of those with high serum PAP had bone metastasis． From
this， PAP was not more specific or sensitive than TAP．
    3． The serum AlkP was high in 52．2％ of the patients with bone metastasis and 5．9％
of those without bone metastasis． High percentage （85．7 ％） of those with high AlkP had bone
rnetastasis．
    4． The serum LDH was high in 55％ of the metastasis group and in 21．4％ of the group
without metastasis， being totally in 30％． Although ne tumor specificity was recognized， the
fact that 64．7％ of the patient with the elevated LDH showed bone metastasis suggests its
significance as one of the indices of extention of cancer．
    5． TAP of the bone marrow fluid was higher than that of the serum in 8 of 9 patients
examined． Bone marrow／serum ratio of TAP was 122．8％ in the non－！netastasis group and
130．5％ in the metastasis group， one of the cases reaching as high as 472．5％．
    6． PAP of the bone marrow fluid was lower than that of the serum in 30f 4 patients
without metastasis． The average ratio was 83．7％． On the other hand， 4 of 5 patients with
metastasis demonstrated PAP higher in the bone marrow． fluid than in the serum． The highest
ratio recorded was 1161．3％， and the average was 127．0％．
    7． The bone marrow LDH was higher than the serum LDH in all 8 cases examined． The
marrow／serurn ratio was 205．8％ in the patients without metastasis and 252．2％ in those with
metastasis．
    8． The changes of the bone marrow enzymes seemed to prececle those of the serum
enzymes． The bone rnarrow study might be clinica11y sigriificant as one of the biochetnical
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biopsies．
  9． Elevation of all of three， enzymes， the serum TAP， PAP， and AlkP， was seen only in
2．7 ％ of the patients without bone metastasis and in 52．2 ％ in those with bone metastasis． When－
ever three enzymes are high， the presence of matastatic bone lesion can be highly suggested．
  10． Five years survival rate of the patients with normal enzyme level was estimated．
Those having normal TAP showed 54．2％being a1皿Qst same as those without bone metastasis．
The patient with normal AlkP showed 39．5％ and those with normal LDH 40．5％．
  11． Five years survival rate of the patients with high enzyme level was as follows． The
high TAP group showed 15．3％， the high AlkP group O％ and the high LDH group also O％．






































































































Table 1． TAP values in case of prostatic cancer

























Table 2．PAP values in cases of prestatic cancer
with or without bone metastasis．
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 Fig． 1．TAP values in prostatic cancer．








AlkP values in cases of prostatic cancer
with or wi’thout bone metastasis，
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Table 4， LDH values in cases of prostatic cancer
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Fig． 4． LDH （Hill－Shibata’s method） values in
    prostatic cancer．
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L＿⊥ニ一一 eFig． 5． ’LDH （Shibata’s method） values in




































Table 5． TAP， PAP and LDH levels in the bone marrow fiuid and blood serum．
Nff． IAgJaglo62geTAp［MTAp i MTA，P．／．，1 spAp l MpAp l MP－A，P6AIP一！ Sft．HMLDHMLDH／  SLDH
1 61 『 6．ou 9．2U 153．3％ 4．1U 3．7u 90．2％ 144U4201ユ 29L8％
2 72 一 9．9u 8．6u 86．9％ 6．4U 2．lu 32．9％ 232u494u212．9％
3 69 一 11．9U 14．6u139．5％ 8．6U11．5U ユ33．7％ 275u405U 147．3％
4 66 一 4．4u 4．9U ！11．4％ 2．7U 2．1u 77．8％ 193u 330u171．．Q％
5 72 十 15．ou20．OU 133．3％ 10．Ou20．Ou 2QO ％ 240u 523u217．9％
6 78 十 1476u 1692U107．6％1434u1650U115．1％ 295u 905u306．8％
7 83 十 9．8u 12．1U 123．4％ 9．8u11．2u 114．3％ 178U310u 174．2％
8 73 十 6．4u 10．1u157．8％ 5．1U 4．Ou 78．4％ 182u564U 309．9％




























Table 6． Relation between bone metastasis and phosphatases．
Bone metastasisNo． of Cases
Elevated phosphatase






























Table 7． 5 years－survivals in relation to TAP， ’AlkP， LDH and bone metastasis．
愉＼lN椰1Elevated l Normal        l Elevated T’A－PV－1 一’A’1’R－p一’ 1一一）L’i－k－PNormaH EIevated l Without 1 WithLDH 1 LDH 1 bone meta．1 bone meta．
・一 86．8 79．1 90．5 6・．・1 87．0 74．2 93．7 80．0
％～1 86．8 61．5 84．3 45．0 80．6 59．4 87．2 66．6
1～2 82．2 41．0 81．1 9．Q 73．8 3Q．9 83．5 26．0
2～3 73．1 24．6 62．6 9．0 62．2 13．6 75．3 17．3
3～4 6L4 15．3 48．7 0 46．7 0．6 62．4 17．3
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